Long Run Wealth Advisors LLC Has $1.57 Million Position in Pfizer Inc. $PFE

Long Run Wealth Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 11.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,645 shares of the biopharmaceutical company’s stock after buying an additional 6,409 shares during the period. Long Run Wealth Advisors LLC’s holdings in Pfizer were worth $1,567,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter worth approximately $27,000. Curio Wealth LLC lifted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer in the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC purchased a new position in Pfizer in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.4%

PFE opened at $24.64 on Thursday. The stock has a market cap of $140.09 billion, a PE ratio of 13.11, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.99. The business’s fifty day simple moving average is $24.74 and its 200 day simple moving average is $24.33.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.